By a News Reporter-Staff News Editor at Clinical Trials Week Patients who experienced a certain type of heart attack who received the anticoagulant fondaparinux had a lower risk of major bleeding events and death both in the hospital and after six months compared to patients who received low-molecular-weight heparin, although both groups had simi
Ardelyx reported financial results for the fourth quarter and twelve months ended December 31, 2014. "We continue to work diligently with AstraZeneca to support the clinical development for tenapanor, and plan to report the results of the Phase 2 a clinical trial in CKD patients in the second quarter of 2015. We are also accelerating the developme
Release date- 02032015- Athersys, Inc. and Chugai Pharmaceutical Co., Ltd. have announced a partnership and license agreement to exclusively develop and commercialize MultiStem cell therapy for ischemic stroke in Japan. Athersys' proprietary cell therapy product, MultiStem, is currently being evaluated in a Phase 2 clinical study for ischemic strok
By a News Reporter-Staff News Editor at Anti-Infectives Week Dipexium Pharmaceuticals, Inc., announced successful completion and initial results of DPX-120, a Phase 1 skin sensitization trial of Locilex , the Company's novel, broad-spectrum topical antibiotic peptide. Visual skin irritation assessments were performed by trained and blinded...
Eric Rowinsky was previously the Chief Medical Officer for ImClone Systems. Dr. Rowinsky is currently the Chief Medical Officer and Head of Research and Development of Stemline Therapeutics, Inc. Dr. Rowinsky has more than 25 years of experience managing clinical trials and developing drugs in oncology, including leading FDA approval of Erbitux
ENGAGE Randomized Clinical Trial Evaluating Cerdelga eliglustat for Treatment-Naive Patients with Gaucher Disease Type 1 Published in The Journal of the American Medical Association. By a News Reporter-Staff News Editor at Biotech Business Week Genzyme, a Sanofi company, announced the publication of results from the ENGAGE registration study..
By a News Reporter-Staff News Editor at Biotech Business Week Genentech, a member of the Roche Group, announced the U.S. Food and Drug Administration has accepted and granted Priority Review for the company's New Drug Application for cobimetinib in combination with Zelboraf for the treatment of people with BRAF V600 mutation-positive advanced
Findings in the Area of Psoriasis Reported from Nottingham University Hospital NHS Trust. By a News Reporter-Staff News Editor at Clinical Trials Week New research on Papulosquamous Skin Diseases is the subject of a report. Our news journalists obtained a quote from the research from Nottingham University Hospital NHS Trust, "To assess the potent
According to news originating from Sapporo, Japan, by NewsRx correspondents, research stated, "Interstitial lung diseases complicated with PM or DM are frequently aggressive and refractory to treatment. Our news journalists obtained a quote from the research from Hokkaido University Hospital, "However, little evidence has yet shown the efficacy of.
By a News Reporter-Staff News Editor at Pharma Business Week Eli Lilly and Company has accepted the recommendation of the ACCELERATE study academic executive committee, based on emerging science in the cardiovascular field, to extend the Phase 3 trial of the investigational medicine evacetrapib by approximately six months. Last patient visit in..
By a News Reporter-Staff News Editor at Pharma Business Week Navidea Biopharmaceuticals, Inc., announced the peer-reviewed publication of results from a Phase 3 clinical trial of Lymphoseek injection in patients with certain head and neck cancer in the journal Annals of Surgical Oncology. This procedure, however, is quite invasive and carries
By a News Reporter-Staff News Editor at Clinical Trials Week DALLAS- UT Southwestern Medical Center scientists have identified a new biomarker that could help identify patients who are more likely to respond to certain chemotherapies. Ryan Potts, Assistant Professor of Physiology, Biochemistry, and Pharmacology, and a member of the Harold C. Simm
By a News Reporter-Staff News Editor at Clinical Trials Week MediVector, Inc. announced it has successfully completed enrollment in two FAVOR favipiravir Phase 3 studies in adults with uncomplicated influenza. The two studies enrolled 2,021 patients in participating clinics and practices in the Americas, Europe, Australia, New Zealand and South A
New Clinical Trials and Studies Findings from Osaka Medical Center for Cancer and Cardiovascular Diseases Reported. By a News Reporter-Staff News Editor at Clinical Trials Week Current study results on Clinical Research have been published. According to news originating from Osaka, Japan, by NewsRx correspondents, research stated, "...
New Clinical Trials and Studies Study Findings Have Been Reported by Researchers at University of Basel Hospital. According to news reporting from Basel, Switzerland, by NewsRx journalists, research stated, "Nutrition plays an important role in osteoporosis prevention and treatment. The news correspondents obtained a quote from the research from th
By a News Reporter-Staff News Editor at Clinical Trials Week New research on Drugs and Therapies is the subject of a report. According to news reporting from Wilmington, Delaware, by NewsRx journalists, research stated, "Gout is a chronic inflammatory condition associated with poor urate metabolism. Treatment success was defined as patient achiev
New Pharmacology and Therapeutics Findings from University of Montpellier I Described. By a News Reporter-Staff News Editor at Clinical Trials Week Researchers detail new data in Drugs and Therapies. According to news reporting originating in Montpellier, France, by NewsRx journalists, research stated, "Urothelial carcinoma of the bladder is the
New Post-Trial Research Study Findings Recently Were Reported by Researchers at Monaldi Hospital. According to news reporting from Naples, Italy, by NewsRx journalists, research stated, "Single-access laparoscopic surgery is not used routinely for the treatment of colorectal disease. The news correspondents obtained a quote from the research from..
By a News Reporter-Staff News Editor at AIDS Vaccine Week A clinical trial called HVTN 100 has been launched in South Africa to study an investigational HIV vaccine regimen for safety and the immune responses it generates in study participants. The HVTN 100 vaccine regimen was designed to provide greater protection than the RV144 regimen and has
By a News Reporter-Staff News Editor at AIDS Weekly Two new clinical trials are examining the safety and acceptability of antiretroviral medicines administered via injection as a means of protecting against HIV infection. The studies are being funded by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of
Release date- 27022015- Amgen and its subsidiary Onyx Pharmaceuticals, Inc., today announced the results from a planned interim analysis showing that the Phase 3 head-to-head clinical trial ENDEAVOR evaluating Kyprolis for Injection in combination with low-dose dexamethasone versus Velcade and low-dose dexamethasone met the primary endpoint of...
Release date- 27022015- Otsuka Pharmaceutical Co., Ltd. and its affiliate Otsuka Canada Pharmaceutical Inc. announce that Health Canada has approved JINARC as the first pharmaceutical agent for the treatment of autosomal dominant polycystic kidney disease. The Health Canada approval of JINARC is based on the results of the pivotal Phase 3 randomize
By a News Reporter-Staff News Editor at Clinical Trials Week PAREXEL International Corporation, a leading global biopharmaceutical services provider, announced the continued expansion of its clinical trial site alliance network, an extensive network of investigator sites and Site Management Organizations that enables PAREXEL to quickly access and
By a News Reporter-Staff News Editor at Pharma Business Week Xi'an Libang Pharmaceutical Technology Co., Ltd. has been issued patent number 8956659, according to news reporting originating out of Alexandria, Virginia, by NewsRx editors. This patent was filed on October 17, 2013 and was published online on February 17, 2015. From the background in
By a News Reporter-Staff News Editor at Pharma Business Week Pfizer Inc. announced that the U.S. Food and Drug Administration has accepted for review the New Drug Application for ALO-02, extended-release capsules, an abuse-deterrent formulation opioid for the management of pain severe enough to require daily, around-the-clock, long-term opioid...